Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer

The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed...

Full description

Bibliographic Details
Main Authors: Otília Menyhárt, Lőrinc Sándor Pongor, Balázs Győrffy
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Pharmacology
Subjects:
TTK
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01522/full
id doaj-683915b769cd4d2eaf589f282c0ad7c9
record_format Article
spelling doaj-683915b769cd4d2eaf589f282c0ad7c92020-11-25T00:16:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-01-01910.3389/fphar.2018.01522430580Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric CancerOtília Menyhárt0Otília Menyhárt1Lőrinc Sándor Pongor2Lőrinc Sándor Pongor3Balázs Győrffy4Balázs Győrffy52nd Department of Pediatrics, Semmelweis University, Budapest, HungaryMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary2nd Department of Pediatrics, Semmelweis University, Budapest, HungaryMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary2nd Department of Pediatrics, Semmelweis University, Budapest, HungaryMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, HungaryThe immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed to uncover mutations associated with elevated PD-L1 expression in GC patients. Data from 410 GC patients were available, including the mutational spectrum of 39,916 genes and expression values of 20,500 genes. PD-L1 gene expression was compared to the mutational status of each gene separately by using a Mann-Whitney U-test and a Receiver Operating Characteristic test. Only mutations with a prevalence over 5% were considered. Significance was accepted in cases of p < 1E-05 and a fold change over 1.44. Mutations in 209 genes were associated with increased PD-L1 expression. These mutations were enriched in genes related to microtubule-based movement (p = 3.4E-4), cell adhesion (p = 4.9E-4), response to DNA-damage (p = 6.9E-4), and double-strand break-repair (p = 1.6E-3). Mutations in TTK (p = 8.8E-10, AUC = 0.77), COL7A1 (p = 2.0E-9, AUC = 0.74), KIF15 (p = 2.5E-9, AUC = 0.75), and BDP1 (p = 3.3E-9, AUC = 0.74) had the strongest link to elevated PD-L1 expression. Finally, we established a decision tree based on mutations in PIK3CA, MEF2C, SLC11A1, and KIF15 capable to separate patient sub-cohorts with elevated PD-L1 expression. In summary, we identified mutations associated with elevated PD-L1 expression that facilitate the development of better prognostic biomarkers for GC, and might offer insight into the underlying tumor biology.https://www.frontiersin.org/article/10.3389/fphar.2018.01522/fullimmunotherapystomach cancerimmune checkpoint inhibitorsCD274PIK3CATTK
collection DOAJ
language English
format Article
sources DOAJ
author Otília Menyhárt
Otília Menyhárt
Lőrinc Sándor Pongor
Lőrinc Sándor Pongor
Balázs Győrffy
Balázs Győrffy
spellingShingle Otília Menyhárt
Otília Menyhárt
Lőrinc Sándor Pongor
Lőrinc Sándor Pongor
Balázs Győrffy
Balázs Győrffy
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
Frontiers in Pharmacology
immunotherapy
stomach cancer
immune checkpoint inhibitors
CD274
PIK3CA
TTK
author_facet Otília Menyhárt
Otília Menyhárt
Lőrinc Sándor Pongor
Lőrinc Sándor Pongor
Balázs Győrffy
Balázs Győrffy
author_sort Otília Menyhárt
title Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
title_short Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
title_full Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
title_fullStr Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
title_full_unstemmed Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
title_sort mutations defining patient cohorts with elevated pd-l1 expression in gastric cancer
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2019-01-01
description The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed to uncover mutations associated with elevated PD-L1 expression in GC patients. Data from 410 GC patients were available, including the mutational spectrum of 39,916 genes and expression values of 20,500 genes. PD-L1 gene expression was compared to the mutational status of each gene separately by using a Mann-Whitney U-test and a Receiver Operating Characteristic test. Only mutations with a prevalence over 5% were considered. Significance was accepted in cases of p < 1E-05 and a fold change over 1.44. Mutations in 209 genes were associated with increased PD-L1 expression. These mutations were enriched in genes related to microtubule-based movement (p = 3.4E-4), cell adhesion (p = 4.9E-4), response to DNA-damage (p = 6.9E-4), and double-strand break-repair (p = 1.6E-3). Mutations in TTK (p = 8.8E-10, AUC = 0.77), COL7A1 (p = 2.0E-9, AUC = 0.74), KIF15 (p = 2.5E-9, AUC = 0.75), and BDP1 (p = 3.3E-9, AUC = 0.74) had the strongest link to elevated PD-L1 expression. Finally, we established a decision tree based on mutations in PIK3CA, MEF2C, SLC11A1, and KIF15 capable to separate patient sub-cohorts with elevated PD-L1 expression. In summary, we identified mutations associated with elevated PD-L1 expression that facilitate the development of better prognostic biomarkers for GC, and might offer insight into the underlying tumor biology.
topic immunotherapy
stomach cancer
immune checkpoint inhibitors
CD274
PIK3CA
TTK
url https://www.frontiersin.org/article/10.3389/fphar.2018.01522/full
work_keys_str_mv AT otiliamenyhart mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer
AT otiliamenyhart mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer
AT lorincsandorpongor mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer
AT lorincsandorpongor mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer
AT balazsgyorffy mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer
AT balazsgyorffy mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer
_version_ 1725382305605746688